A Phase 2 interventional study of ENTR-601-44 and ENTR-601-45 in Duchenne Muscular Dystrophy (DMD), sponsored by Entrada Therapeutics, Inc.. Not yet recruiting at 17 sites in 5 countries. Open to male participants aged 4 Years to 20 Years. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by Entrada Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Muscular Dystrophy, Duchenne with a site in United Kingdom — 16 open to participants now, 26 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United Kingdom.
Among the 85 studies in Muscular Dystrophy, Duchenne with a site in United Kingdom, this one is the 33rd largest by planned enrollment of the 73 interventional ones that give a count, is one of 4 that started in 2026, is one of 23 in phase 2, reaches primary completion later than 24 of the 25 other live ones, and was the 85th registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →16 of the 85 studies in Muscular Dystrophy, Duchenne with a site in United Kingdom are open now. Recruiting first, the newest first:
Avidity Biosciences, Inc. · Sites in United Kingdom, Australia, Belgium and 7 more countries
Ages 7–16 · Men only
University of Oxford · Sites in United Kingdom
Ages 1–3 · Men only · Healthy volunteers
Solid Biosciences Inc. · Sites in United Kingdom, United States, Australia and 3 more countries
Ages 7–11 · Men only
Entrada Therapeutics, Inc. · Sites in United Kingdom, Belgium, Italy and 2 more countries
Ages 4–20 · Men only
Entrada Therapeutics, Inc. · Sites in United Kingdom, Belgium, Italy and 1 more country
Ages 4–20 · Men only
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: 4 Years to 20 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 37 · Phase 3 31 · Phase 4 1
First in 2007; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 74 across the 73 interventional studies, 85 across the 11 observational. Of the 56 that completed or were terminated, 32 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
68 of 85 have an industry lead sponsor. The 10 most frequent:
Entrada Therapeutics, Inc. is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Entrada Therapeutics, Inc. has 3 studies filed under Muscular Dystrophy, Duchenne — fewer than ten, so there is no comparison to draw.
5 of the studies in Muscular Dystrophy, Duchenne with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881408Phase 3Sarepta Therapeutics, Inc.A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | 2027-05-31 |
| NCT07287189Satellos Bioscience, Inc.Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients | 2027-03-31 |
| NCT06280209BioMarin PharmaceuticalA Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy | 2027-04-14 |
| NCT06138639Solid Biosciences Inc.A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE) | 2027-05-06 |
| NCT07423026University of OxfordA Remote Study Using Technology to Assess Outcomes in DMD | 2027-10-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 85 studies in Muscular Dystrophy, Duchenne with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a study of investigational medicines ENTR-601-44 and ENTR-601-45 designed to evaluate the long-term safety and tolerability of study drugs in participants with Duchenne muscular dystrophy (DMD).
The investigational medicines are currently being investigated in multiple ascending dose parent studies. After participants complete their respective parent study, there is a need to understand the effects of long-term administration of ENTR-601-44 and ENTR-601-45.
Participants enrolling in this study will begin this long-term extension (LTE) study at the dose level they received upon completion of the parent study with possible dose escalation in the LTE study based on emerging safety and efficacy data from the parent studies.
Participants will:
Participants are allowed to continue receiving their standard of care therapy for DMD during the study, as long as their health remains stable.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ENTR-601-44 intravenous infusion every 6 weeks
Drug: ENTR-601-44
ENTR-601-45 intravenous infusion every 6 weeks
Drug: ENTR-601-45
ENTR-601-44 intravenous infusion
ENTR-601-45 intravenous infusion
Number of participants with Treatment Emergent Adverse Events (TEAEs) according to study protocol (Part A and OL Period)
Safety will be assessed by monitoring adverse events, physical examination, vital signs and clinical laboratory tests.
Time frame: From baseline through End of Study (up to 2 years).
Plasma concentration of study drug compounds and their final metabolite
Time frame: From baseline through End of Study (up to 2 years).
Change from parent study Part A and OL Period baselines to LTE EOS in 10-Meter Walk/Run (10MWR)
Time frame: From baseline through End of Study (up to 2 years).
Change from parent study Part A and OL Period baselines to LTE EOS in timed rise from floor (TRF)
Time frame: From baseline through End of Study (up to 2 years).
Change from parent study Part A and OL Period baselines to LTE EOS in Timed 4-Stair Climb (4SC)
Time frame: From baseline through End of Study (up to 2 years).
Change from parent study Part A and OL Period baselines to LTE EOS in stride velocity 95th centile (SV95C)
Time frame: From baseline through End of Study (up to 2 years).
Change from parent study Part A and OL Period baselines to LTE EOS in North Star Ambulatory Assessment (NSAA)
Time frame: From baseline through End of Study (up to 2 years).
Change from parent study Part A and OL Period baselines to LTE EOS in Performance of the Upper Limb v2.0 (PUL 2.0)
Time frame: From baseline through End of Study (up to 2 years).
Anti-drug antibody (ADA) and anti-dystrophin antibody in serum
Time frame: From baseline through End of Study (up to 2 years).
Plan to share: No — The datasets generated during and/or analyzed during the current study are not expected to be made available due to the data´s high commercial sensitivity.
No publications or documents are linked to this record.
Start is estimated for Aug 2026; primary completion for Mar 2032, 67 months later.
Of 40 industry-sponsored phase 2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's planned 67 months is above that.
Counting every sponsor, half of 47 studies reached it within 31 months; a quarter within 20 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Muscular Dystrophy, Duchenne →
Entrada Therapeutics, Inc.